Clinical Trial Update: First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI [Phase 1, Phase 2]

View source ↗

Summary

First-in-human Phase 1/2 trial of BBT-207 in EGFR-mutant advanced non-small cell lung cancer after prior EGFR TKI therapy is underway.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BBT-207

Snippet

Sponsor: Bridge Biotherapeutics, Inc. | Conditions: EGFR Mutant Advanced Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING